Expedited Access to Biosimilars Act
Summary
The Expedited Access to Biosimilars Act would reduce clinical study requirements for biosimilar approval, lowering development costs and time to market for biosimilar manufacturers. This is bullish for companies like Viatris ($VTRS), Amgen ($AMGN), and Pfizer ($PFE) that have significant biosimilar pipelines.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Bill eliminates mandatory immunogenicity, pharmacodynamics, and comparative efficacy studies for biosimilars, reducing development costs.
- 2.FDA retains ability to require such studies with written justification, balancing speed and safety.
- 3.Biosimilar-focused companies like Viatris ($VTRS) are primary beneficiaries; Amgen ($AMGN) and Pfizer ($PFE) also have exposure.
Market Implications
The bill is structurally bullish for biosimilar developers. $VTRS, with its deep biosimilar pipeline and higher sensitivity to regulatory changes, is the most leveraged play. $AMGN and $PFE have broader portfolios but still benefit. The stock reactions will depend on passage probability; near-term, the committee advancement is a positive signal but not a catalyst until floor votes. No real market price data is provided, so no fabricated moves.
Full Analysis
On July 22, 2026, the Senate Committee on Health, Education, Labor, and Pensions ordered the Expedited Access to Biosimilars Act (S.1414) to be reported favorably with an amendment. The bill, sponsored by Sen. Rand Paul (R-KY) and cosponsored by Sens. Mike Lee (R-UT) and Maggie Hassan (D-NH), now awaits floor action in the Senate. The legislation amends the Public Health Service Act to eliminate the requirement that clinical studies for biosimilar licensure include assessments of immunogenicity, pharmacodynamics, or comparative clinical efficacy. Instead, the FDA may require such studies at its discretion only with a written justification notice.
There is no direct funding in this bill—it is a regulatory relief measure. By reducing mandatory clinical trial requirements, the bill lowers the cost and time to bring biosimilars to market. This directly benefits biosimilar developers by accelerating approval timelines and reducing development costs, which can total hundreds of millions per product. Originator biologic makers may face increased competition, but the net impact on diversified pharma companies depends on their biosimilar exposure.
The bill has bipartisan support and advanced from committee swiftly (from introduction in April 2025 to committee markup in July 2026). Next steps: Senate floor vote, then House passage. Given the bipartisan co-sponsorship and relatively narrow scope, passage is plausible in the current Congress.
Structural winners are pure-play biosimilar and generic companies with large biosimilar pipelines. Viatris ($VTRS) derives ~20% of revenue from biosimilars and generics; lower regulatory burden could expand margins and speed launches. Amgen ($AMGN) has both originator and biosimilar businesses, but its biosimilar segment is growing and stands to benefit. Pfizer ($PFE) has a smaller biosimilar portfolio but could see incremental cost savings. The measured approach—FDA retains discretion—reduces risk of lower safety standards, which may ease opposition.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
regulatory exemption from clinical study requirements for immunogenicity, pharmacodynamics, and comparative clinical efficacy in biosimilar applications
Who must act
FDA and biosimilar applicants under the Public Health Service Act
What happens
Reduced clinical trial costs and time to market for biosimilar products; FDA retains discretion to require such studies with written justification
Stock impact
Viatris ($VTRS) has a significant biosimilar portfolio including Semglee and Hulio; lower development costs and faster FDA approval would accelerate revenue from pipeline biosimilars, improving profit margins on these products.
What the bill does
regulatory exemption from clinical study requirements for immunogenicity, pharmacodynamics, and comparative clinical efficacy in biosimilar applications
Who must act
FDA and biosimilar applicants under the Public Health Service Act
What happens
Reduced clinical trial costs and time to market for biosimilar products; FDA retains discretion to require such studies with written justification
Stock impact
Amgen ($AMGN) has a biosimilar portfolio including Mvasi, Kanjinti, and others; the exemption lowers development costs and could speed biosimilar launches, enhancing revenue growth from biosimilars which currently contribute ~$1.5B annually.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Affordable Prescriptions for Patients Act
A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →